200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study
Summary
Host Dave Knapp contextualizes reports of over 200 UK deaths linked to GLP-1s, analyzing the tragic case of 19-year-old Josephine Nassar to distinguish correlation from causation. He discusses actress Chrissy Metz’s public embrace of weight-loss medication and a Harvard study revealing the "obesity penalty" in hiring and relationships. Finally, Knapp addresses Starbucks’ decision to drop GLP-1 coverage for obesity, highlighting the growing tension between employer costs and patient access to chronic disease treatment.
Topics discussed
Intro: UK deaths, Chrissy Metz, and Harvard study
Sponsor segment: VOA Fit and MyLevel app
Context on 200+ UK deaths and Josephine Nassar
Josephine's background and the IV fluid incident
The inquest findings and unanswered questions
Myocardial bridging and the chain of events
Balancing safety concerns with patient advocacy
Breaking down the 216 fatal reports and denominators
Pharmacovigilance and warning about GI side effects
Chrissy Metz's GLP-1 announcement and public reaction
Harvard study on the 'Obesity Penalty' in hiring
Employer coverage trends: Starbucks vs. Bank of America
Call to action and show schedule
Sponsor ads: Nesquik, Verizon, and Fiori
Listen ad-free on Castria